Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Revolution Medicines (RVMD) Equity Ratio (2019 - 2025)

Revolution Medicines has reported Equity Ratio over the past 7 years, most recently at 0.69 for Q4 2025.

  • Quarterly results put Equity Ratio at 0.69 for Q4 2025, down 21.75% from a year ago — trailing twelve months through Dec 2025 was 0.69 (down 21.75% YoY), and the annual figure for FY2025 was 0.69, down 21.75%.
  • Equity Ratio for Q4 2025 was 0.69 at Revolution Medicines, down from 0.71 in the prior quarter.
  • Over the last five years, Equity Ratio for RVMD hit a ceiling of 0.9 in Q1 2024 and a floor of 0.69 in Q4 2025.
  • Median Equity Ratio over the past 5 years was 0.87 (2021), compared with a mean of 0.84.
  • Biggest five-year swings in Equity Ratio: grew 11.44% in 2021 and later dropped 21.75% in 2025.
  • Revolution Medicines' Equity Ratio stood at 0.82 in 2021, then increased by 3.36% to 0.84 in 2022, then grew by 4.96% to 0.89 in 2023, then dropped by 0.04% to 0.89 in 2024, then decreased by 21.75% to 0.69 in 2025.
  • The last three reported values for Equity Ratio were 0.69 (Q4 2025), 0.71 (Q3 2025), and 0.77 (Q2 2025) per Business Quant data.